Michael Gutch has joined the life sciences investment group at Miami-based HIG Ventures, the venture capital affiliate of HIG Capital.
Prior to joining HIG, Gutch was a principal with Lilly Ventures, the corporate venture capital group of Eli Lilly, where he focused on early-stage investments in biopharmaceutical companies. During this time, he also previously served as a board director for Protagonist Therapeutics and board observer for Hydra Biosciences and Calistoga Pharmaceuticals.
Prior to his time with Eli Lilly, Gutch was employed by Genentech and Spring Mill Venture Partners. He holds a PhD in cellular and molecular pathology from the State University of New York, and conducted his postdoc at the University of California, San Francisco, and Cold Spring Harbor Laboratory.